04:53 PM EDT, 06/24/2025 (MT Newswires) -- Verastem ( VSTM ) said late Tuesday it has dosed the first patient in its US phase 1/2a trial of VS-7375, an investigational oral inhibitor targeting KRAS G12D mutant solid tumors.

The study is designed to assess the safety and efficacy of VS-7375 and is being conducted in the US with plans for global expansion. It builds on encouraging early results from a phase 1/2 trial in China conducted by Verastem's ( VSTM ) partner, GenFleet Therapeutics.

The US monotherapy dose-escalation phase will begin with a 400-milligram dose, matching an efficacious level identified in the China study. Verastem ( VSTM ) plans to escalate dosing based on safety and efficacy outcomes, and, if successful, move to a phase 2 expansion in advanced pancreatic and non-small cell lung cancers.

VS-7375 will be evaluated both as a standalone treatment and in combination with cetuximab in advanced solid tumors. Based on the results of the combination phase, Verastem ( VSTM ) said it plans to initiate an expansion cohort in colorectal cancer.

Shares of Verastem ( VSTM ) were up more than 5% in after-hours trading.